Quoin Pharmaceuticals (FRA:2EB0) 5-Year Sharpe Ratio: N/A (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2EB0 Quoin Pharmaceuticals Ltd FRA:2EB0
29 GF Score
Price €5.90
! 1 Warning Sign
View Full Analysis

What is Quoin Pharmaceuticals 5-Year Sharpe Ratio?

The 5-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past five years. As of today (2026-09-22), Quoin Pharmaceuticals's 5-Year Sharpe Ratio is Not available.

Quoin Pharmaceuticals  (FRA:2EB0) 5-Year Sharpe Ratio Explanation

The 5-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past five years. It is calculated as the annualized result of the average five-year monthly excess returns divided by its standard deviation in the five-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Quoin Pharmaceuticals 5-Year Sharpe Ratio Related Terms

FRA:2EB0 vs BCLI, MBRX, ASBP: 5-Year Sharpe Ratio Comparison

For the Biotechnology subindustry, Quoin Pharmaceuticals's 5-Year Sharpe Ratio, along with its competitors' market caps and 5-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Quoin Pharmaceuticals 5-Year Sharpe Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Quoin Pharmaceuticals's 5-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Quoin Pharmaceuticals's 5-Year Sharpe Ratio falls into.


FRA:2EB0
29GF Score
Quoin Pharmaceuticals Ltd FRA:2EB0
5-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Quoin Pharmaceuticals 5-Year Sharpe Ratio Calculation

The 5-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last five years. A stock / portfolio's 5-Year Sharpe Ratio can be calculated by dividing the difference between the five-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past five years.

Quoin Pharmaceuticals Business Description

Other Exchanges QNRX:USA
Address 42127 Pleasant Forest Court, Ashburn, VA, USA, 20148-7349
Quoin Pharmaceuticals Ltd is a clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products for rare and orphan diseases, particularly those involving skin and dermatological conditions. Its lead product candidate, QRX003, is a topical lotion being developed for Netherton Syndrome, a rare genetic skin disorder, and the company is also exploring its use in other rare skin conditions such as Peeling Skin Syndrome, Palmoplantar Keratoderma, and Epidermolysis Bullosa. The company operates as a development-stage business, meaning it does not yet generate significant product revenue and relies on financing activities to fund its research, clinical trials, and regulatory efforts. Quoin Pharmaceuticals is headquartered in the United States and is listed on the Nasdaq Capital Market under the ticker QNRX.
29GF Score

Get the complete analysis for FRA:2EB0

5-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.90
Price